BIOLOGICAL · Unmapped registry intervention
Nivolumab
Find medicine records ·
Find other trials using this name
Clinical trial
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
NCT01642004
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedStudy of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Squamous Cell Non-small Cell Lung Cancerunresolved
Interventions
NivolumabBIOLOGICAL
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Bristol-Myers Squibblead sponsor
Mapped research locations
SeattleWashington, United States4New YorkNew York, United States3BostonMassachusetts, United States3NashvilleTennessee, United States3MoscowRussia3PhiladelphiaPennsylvania, United States2DallasTexas, United States2BaltimoreMaryland, United States2MadridSpain2TampaFlorida, United States2DurhamNorth Carolina, United States2New HavenConnecticut, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01642004 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.